Bonum Well being(TM), LLC (a TRxADE HEALTH Firm) Reaffirms its Dedication to Impartial Pharmacies and Group Buying Organizations (GPOs) with its Novel Telemedicine Companies Mannequin

TAMPA, FL / ACCESSWIRE / December 6, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)(“TRxADE” or the “Firm”) an built-in drug procurement, supply, and healthcare platform, as we speak introduced that Bonum Well being, a Digital Healthcare enterprise subsidiary, has signed a most well-liked telemedicine companies settlement with an unbiased group buying group (GPO) which is able to present deep reductions to entry Bonum Well being’s service platform for 100+ pharmacies and their affected person’s within the northeastern a part of america.

The Firm, which gives nationwide telemedicine companies in all 50 states for people and choose states for pets, has grown its presence with unbiased pharmacies by selling telemedicine companies to its affected person base. Dr. Shafaat Pirani, PharmD, BCGP, Chief Scientific and Compliance Officer for TRxADE states, “We’ve seen a rise in curiosity among the many unbiased pharmacy group who wish to diversify their service choices to sufferers by offering reasonably priced entry to telehealth options for the rising uninsured and under-insured affected person inhabitants. In most states, pharmacists will not be acknowledged as Suppliers with prescriptive authority, and should subsequently submit remedy suggestions to the prescriber, which regularly results in delays in remedy which can result in adversarial outcomes for sufferers. The flexibility to attach a affected person with a telemedicine supplier utilizing our cellular utility, for a easy remedy refill or to prescribe an acute course of antibiotics or steroids for an an infection, is the kind of comfort we consider sufferers are in search of in as we speak’s digital atmosphere.”

Dr. Pirani went on to additional talk about that, “We’ve seen that unbiased pharmacies that don’t present in-house scientific companies are shedding sufferers to the enterprise pharmacy chains, like CVS Well being’s Well being Hub Mannequin or through Walgreen’s Village MD Clinic Partnership, the place sufferers can stroll in and shortly see a supplier in particular person. We’re working to offer an answer to this downside for the nation’s unbiased pharmacies, by strategically working with and recruiting GPOs to advertise Bonum Well being’s service providing, whereas additionally offering deeper reductions to sufferers primarily based on market share. Our technique is targeted on garnering strategic business-to-business (B2B) alternatives like this, and we consider we’ve got a number of alternatives within the rapid pipeline.”

Story continues

Suren Ajjarapu, Chairman and Chief Government Officer of TRxADE added, “We’re happy to see such a optimistic response from the unbiased pharmacy group. Our mission at TRxADE has been to empower the unbiased pharmacy market by offering price financial savings on pharmaceutical merchandise, and we see a chance to assist enhance foot site visitors and prescriptions to our community of pharmacies.” Mr. Ajjarapu added, “We’ve operated with success within the business-to-business (B2B) markets and we consider that partnering with unbiased GPOs and shopping for teams will proceed to boost our place and supply worth to our eco-system of pharmacies.”

About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a well being companies IT firm centered on digitalizing the retail pharmacy expertise by optimizing drug procurement, the prescription journey, and affected person engagement within the U.S. The Firm operates the TRxADE drug procurement market serving a complete of 14,100+ members nationwide, fostering value transparency, and beneath the Bonum Well being model, providing patient-centric telehealth services and tele vet services. For info on TRxADE, please go to the Firm’s IR web site at investors.trxadehealth.com.

Ahead-Wanting Statements
This press launch could comprise forward-looking statements, together with details about administration’s view of TRxADE’s future expectations, plans, and prospects, inside the that means of the federal securities legal guidelines, together with the protected harbor provisions beneath The Non-public Securities Litigation Reform Act of 1995. Specifically, when used within the previous dialogue, the phrases “could,” “might,” “anticipate,” “intend,” “plan,” “search,” “anticipate,” “consider,” “estimate,” “predict,” “potential,” “proceed,” “seemingly,” “will,” “would” and variations of those phrases and comparable expressions, or the unfavourable of those phrases or comparable expressions are supposed to determine forward-looking statements. Any statements made on this information launch aside from these of historic truth, about an motion, occasion, or improvement, are forward-looking statements. These statements contain identified and unknown dangers, uncertainties and different elements, which can trigger the outcomes of TRxADE, its divisions, and ideas to be materially completely different from these expressed or implied in such statements. These dangers embody dangers referring to agreements with third events; together with Wakefern Meals Corp., Coborn’s, Galt Prescribed drugs, and others; our means to lift funding sooner or later, as and if wanted, and the supply and phrases of such funding, together with potential dilution precipitated thereby; TRxADE’s means to proceed as a going concern; the deliberate advantages, anticipated customers of and projected revenues of our enterprise with Alternate Well being and different third events; quantities we owe and should owe to Alternate Well being in reference to the association with Alternate Well being; safety pursuits beneath sure of our credit score preparations; the truth that we’re exploring strategic alternate options for our B2C subsidiaries, together with Bonum Well being, Inc.; our means to keep up the itemizing of our frequent inventory on the Nasdaq Capital Market, together with our present non-compliance with the continued itemizing requirements of the Nasdaq Capital Market; dangers related to TRxADE’s operations not being worthwhile; the industrial viability of latest enterprise traces, functions, merchandise and applied sciences, and the prices of such objects; the adoption of the Firm’s product choices; claims referring to alleged violations of mental property rights of others; our means to monetize our technological options; technical issues with our web sites, apps, and merchandise; dangers referring to implementing our acquisition methods; challenges to the pharmaceutical provide chain posted by the COVID-19 pandemic and associated issues; our means to handle our development; unfavourable results on our operations related to the opioid ache remedy well being disaster; regulatory and licensing requirement dangers; dangers associated to modifications within the U.S. healthcare atmosphere; the standing of our info programs, amenities and distribution networks; dangers related to the operations of our extra established rivals; regulatory modifications; new rivals which can have extra sources than we do; will increase in direct to shopper gross sales of medicine; healthcare fraud; COVID-19, governmental responses thereto, financial downturns and elevated inflation and attainable recessions precipitated thereby; modifications in legal guidelines or laws referring to our operations; privateness legal guidelines; system errors; dependence on present administration; our development technique; dilution which can be attributable to future choices; elevated inflation and rates of interest, together with the elevated prices of elevating funding because of this thereof; provide chain points attributable to amongst different issues, recessions and world conflicts; and others which might be included every now and then in filings made by TRxADE with the Securities and Alternate Fee, together with, however not restricted to, within the “Cautionary Observe Concerning Ahead-Wanting Statements” and “Threat Elements” sections in its Type 10-Ks and Type 10-Qs and in its Type 8-Ks, which it has filed, and recordsdata every now and then, with the U.S. Securities and Alternate Fee (SEC), and extra notably within the Quarterly Report on Type 10-Q for the quarter ended September 30, 2022 and our Annual Report on Type 10-Ok for the yr ended December 31, 2021. These stories can be found at www.sec.gov. Different unknown or unpredictable elements additionally might have materials adversarial results on TRxADE’s future outcomes and/or might trigger our precise outcomes and monetary situation to vary materially from these indicated within the forward-looking statements. The forward-looking statements included on this press launch are made solely as of the date hereof. TRxADE can not assure future outcomes, ranges of exercise, efficiency, or achievements. Accordingly, you shouldn’t place undue reliance on these forward-looking statements. We undertake no obligation to replace publicly any of those forward-looking statements to mirror precise outcomes, new info or future occasions, modifications in assumptions, or modifications in different elements affecting forward-looking statements, besides to the extent required by relevant legal guidelines. If we replace a number of forward-looking statements, no inference ought to be drawn that we are going to make further updates with respect to these or different forward-looking statements.

Media Contact/Investor Relations:
IR@trxade.com
Investors.trxadegroup.com
(800) 261-0281

SOURCE: TRxADE HEALTH, INC.

View supply model on accesswire.com:
https://www.accesswire.com/730344/Bonum-HealthTM-LLC-a-TRxADE-HEALTH-Company-Reaffirms-its-Commitment-to-Independent-Pharmacies-and-Group-Purchasing-Organizations-GPOs-with-its-Novel-Telemedicine-Services-Model